Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Behçet's disease medical therapy

Introduction

Overview

Overview

Current treatment is aimed at easing the symptoms, reducing inflammation, and controlling the immune system. Anti-TNF therapy, such as infliximab, has shown promise in treating the uveitis associated with the disease. Another Anti-TNF agent, etanercept, may be useful in patients with mainly skin and mucosal symptoms. Interferon alfa-2a, azathioprine, colchicine, thalidomide, dapsone and rebamipide are among other agents that are used alternatives.

Medical Therapy

Medical Therapy

References

References

  1. ↑ Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001). “Effect of infliximab on sight-threatening panuveitis in Behçet’s disease”. Lancet. 358 (9278): 295–6. PMID 11498218.
  2. ↑ Sfikakis PP (2002). “Behçet’s disease: a new target for anti-tumour necrosis factor treatment”. Ann Rheum Dis. 61 Suppl 2: ii51–3. PMC 1766720. PMID 12379622.
  3. ↑ Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S; et al. (2005). “Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study”. J Rheumatol. 32 (1): 98–105. PMID 15630733.
  4. ↑ Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S; et al. (2002). “Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study”. Arch Dermatol. 138 (4): 467–71. PMID 11939808.
  5. ↑ Kötter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I; et al. (2003). “Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis”. Br J Ophthalmol. 87 (4): 423–31. PMC 1771623. PMID 12642304.
  6. ↑ Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H (2002). “Interferon alfa combined with azathioprine for the uveitis of Behçet’s disease: an open study”. Isr Med Assoc J. 4 (11 Suppl): 928–30. PMID 12455182.
  7. ↑ Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H (2001). “A double-blind trial of colchicine in Behçet’s syndrome”. Arthritis Rheum. 44 (11): 2686–92. PMID 11710724.
  8. ↑ Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (1998). “Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial”. Ann Intern Med. 128 (6): 443–50. PMID 9499327. line feed character in |title= at position 83 (help)
  9. ↑ Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y (2003). “Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study”. Drugs R D. 4 (1): 19–28. PMID 12568631.
  10. ↑ Sharquie KE, Najim RA, Abu-Raghif AR (2002). “Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study”. J Dermatol. 29 (5): 267–79. PMID 12081158.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hamid Qazi, MD, BSc [2]